Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment
Standard
Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment. / Meyer, Christian P; Sun, Maxine; Karam, Jose A; Leow, Jeffrey J; de Velasco, Guillermo; Pal, Sumanta K; Chang, Steven L; Trinh, Quoc-Dien; Choueiri, Toni K.
In: EUR UROL, Vol. 72, No. 2, 08.2017, p. 171-174.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Complications After Metastasectomy for Renal Cell Carcinoma-A Population-based Assessment
AU - Meyer, Christian P
AU - Sun, Maxine
AU - Karam, Jose A
AU - Leow, Jeffrey J
AU - de Velasco, Guillermo
AU - Pal, Sumanta K
AU - Chang, Steven L
AU - Trinh, Quoc-Dien
AU - Choueiri, Toni K
N1 - Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.
PY - 2017/8
Y1 - 2017/8
N2 - Metastasectomy has long been considered a valid treatment option for patients with oligometastatic renal cell carcinoma (oligo-mRCC). However, the literature on complications in this setting is scarce. Our objective was to describe in-hospital complications after metastasectomy in a contemporary cohort of patients with mRCC. Using the National Inpatient Sample database (2000-2011), 45 279 mRCC patients were identified. Of those, 1102 underwent metastasectomies. The metastatic sites were the lungs, bone, liver, lymph nodes, adrenal glands, and brain in, respectively, 52%, 29%, 19%, 14%, 11%, and 3.4% of patients. The overall complication rate was 45.7%. Major complications (Clavien III-V) constituted 27.5%. Resections of hepatic lesions were significantly associated with higher odds of overall complications compared with any other site (odds ratio 2.59, 95% confidence interval 1.84-3.62, p<0.001). While metastasectomy remains a potential treatment option in RCC with oligometastatic disease, the associated complication rates are non-negligible; therefore, careful patient selection is warranted.PATIENT SUMMARY: We studied outcomes of patients with metastatic kidney cancer treated with metastasectomy. While metastasectomy is a treatment option for metastatic renal cell carcinoma, complications are not insignificant and our results may guide preoperative counseling.
AB - Metastasectomy has long been considered a valid treatment option for patients with oligometastatic renal cell carcinoma (oligo-mRCC). However, the literature on complications in this setting is scarce. Our objective was to describe in-hospital complications after metastasectomy in a contemporary cohort of patients with mRCC. Using the National Inpatient Sample database (2000-2011), 45 279 mRCC patients were identified. Of those, 1102 underwent metastasectomies. The metastatic sites were the lungs, bone, liver, lymph nodes, adrenal glands, and brain in, respectively, 52%, 29%, 19%, 14%, 11%, and 3.4% of patients. The overall complication rate was 45.7%. Major complications (Clavien III-V) constituted 27.5%. Resections of hepatic lesions were significantly associated with higher odds of overall complications compared with any other site (odds ratio 2.59, 95% confidence interval 1.84-3.62, p<0.001). While metastasectomy remains a potential treatment option in RCC with oligometastatic disease, the associated complication rates are non-negligible; therefore, careful patient selection is warranted.PATIENT SUMMARY: We studied outcomes of patients with metastatic kidney cancer treated with metastasectomy. While metastasectomy is a treatment option for metastatic renal cell carcinoma, complications are not insignificant and our results may guide preoperative counseling.
KW - Journal Article
U2 - 10.1016/j.eururo.2017.03.005
DO - 10.1016/j.eururo.2017.03.005
M3 - SCORING: Journal article
C2 - 28359734
VL - 72
SP - 171
EP - 174
JO - EUR UROL
JF - EUR UROL
SN - 0302-2838
IS - 2
ER -
